Systemic lupus erythematosus with ischemic peripheral neuropathy and lupus anticoagulant: response to intravenous prostaglandin E1.
We report a case of systemic lupus erythematosus with cutaneous vasculitis and peripheral neuropathy. Results of laboratory examinations revealed lupus anticoagulant in the patient's serum. His lower limbs showed asymmetry. A sural nerve biopsy specimen showed modest degeneration of nerve fibers and incomplete obstruction of nutrient vessels. His cutaneous vasculitis responded to treatment with high-dose corticosteroid, but the lower limb neuropathy responded incompletely. Daily intravenous prostaglandin E1 treatment improved his neurologic and cutaneous symptoms markedly. Our case implied that nutritional vascular ischemia caused by lupus anticoagulant is involved in the pathogenesis of lupus neuropathy in addition to well-known peripheral nerve vasculitis. It also documented the effectiveness of intravenous prostaglandin E1 in the treatment of systemic lupus erythematosus.
Yoshikawa
Y
Y
Department of Dermatology, Mie University, Faculty of Medicine, Japan.
Mizutani
H
H
Shimizu
M
M
D000328:Adult; D000527:Alprostadil / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D007511:Ischemia / Q000209:etiology; D016682:Lupus Coagulation Inhibitor / Q000097:blood*; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D008297:Male; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy / Q000209:etiology*; D011115:Polyneuropathies / Q000188:drug therapy / Q000209:etiology*; D013497:Sural Nerve / Q000098:blood supply; D014665:Vasodilator Agents / Q000627:therapeutic use*
D016682:Lupus Coagulation Inhibitor; D014665:Vasodilator Agents; D000527:Alprostadil